ABSTRACT Background: Evidence from clinical studies has suggested that cocoa may increase high-density lipoprotein (HDL)-cholesterol concentrations. However, it is unclear whether this effect is attributable to flavonoids or theobromine, both of which are major cocoa components. Objectives: We investigated whether pure theobromine increases serum HDL cholesterol and whether there is an interaction effect between theobromine and cocoa. Design: The study had a 2-center, double-blind, randomized, placebo-controlled, full factorial parallel design. After a 2-wk run-in period, 152 healthy men and women (aged 40-70 y) were randomly allocated to consume one 200-mL drink/d for 4 wk that contained 1) cocoa, which naturally provided 150 mg theobromine and 325 mg flavonoids [cocoa intervention (CC)], 2) 850 mg pure theobromine [theobromine intervention (TB)], 3) cocoa and added theobromine, which provided 1000 mg theobromine and 325 mg flavonoids [theobromine and cocoa intervention (TB+CC)], or 4) neither cocoa nor theobromine (placebo). Blood lipids and apolipoproteins were measured at the start and end of interventions. Results: In a 2-factor analysis, there was a significant main effect of the TB (P , 0.0001) but not CC (P = 0.1288) on HDL cholesterol but no significant interaction (P = 0.3735). The TB increased HDLcholesterol concentrations by 0.16 mmol/L (P , 0.0001). Furthermore, there was a significant main effect of the TB on increasing apolipoprotein A-I (P , 0.0001) and decreasing apolipoprotein B and LDL-cholesterol concentrations (P , 0.02). Conclusions: Theobromine independently increased serum HDLcholesterol concentrations by 0.16 mmol/L. The lack of significant cocoa and interaction effects suggested that theobromine may be the main ingredient responsible for the HDL cholesterol-raising effect. This trial was registered at clinicaltrials.gov as NCT01481389. Am J Clin Nutr 2013;97:1201-9.
INTRODUCTION
A number of observational and clinical studies indicated that cocoa or cocoa-containing products may reduce cardiovascular disease (CVD) 4 risk (1) and improve CVD-related risk factors such as blood pressure (2) , LDL oxidation, inflammatory status (3, 4) , and the blood lipid profile (5) (6) (7) . Several clinical studies showed that cocoa increases HDL-cholesterol concentrations (8) (9) (10) (11) (12) (13) , although other studies did not confirm such a beneficial effect (14) (15) (16) (17) (18) (19) (20) . Low serum HDL cholesterol (,1 mmol/L) is considered an independent and inverse CVD risk factor, and beyond lowering LDL cholesterol, increasing HDL cholesterol has been suggested as a secondary lipid target for reducing CVD risk (21) . The cardioprotective effects of cocoa are commonly attributed to cocoa flavonoids, which have been reported to influence various CVD risk factors through multiple mechanistic pathways (3, 4, 22, 23) . However, mechanistic evidence for cocoa flavonoids to affect blood lipids is lacking (4, 22) . In particular, it is not clear whether flavonoids or possibly another bioactive component of cocoa (ie, theobromine) are responsible for the reported increase in serum or plasma HDL-cholesterol concentrations. Strikingly, clinical studies that compared theobromine-containing cocoa products to theobromine-free control products repeatedly showed significant beneficial effects on HDL cholesterol (8) (9) (10) (11) (12) . In contrast, studies with test products that controlled for the theobromine content mostly did not show an effect on increasing HDL cholesterol (14, (16) (17) (18) 20) . These results suggested that theobromine in cocoa, rather than flavonoids, may be involved or even responsible for the HDLcholesterol increasing benefit. Therefore, to investigate whether theobromine by itself or together with cocoa can increase HDL-cholesterol concentrations, we studied the effects of cocoa, pure theobromine, and the combination of cocoa with added theobromine on changes in the blood lipid profile in healthy humans. Because theobromine is known for its vasodilating and cardiac-stimulating function (24, 25) , we also investigated possible effects of theobromine on blood pressure and heart rate.
SUBJECTS AND METHODS

Subjects
Subjects within the subject database of Eurofins Optimed Clinical Research, Grenoble and Lyon, France, who met the major inclusion criteria were contacted and invited for a screening visit. In total, 152 healthy men and postmenopausal women, aged 40-70 y, participated in the study. Participants had 10-y risk of developing CVD ,10% based on the European low-risk chart (26) ; their blood lipids, blood pressure, heart rate, blood glucose, and other biochemical and hematologic variables were within healthy reference ranges as judged by the research physician. Subjects with diabetes or previous cardiovascular events as well as smokers were excluded from the study. Also, subjects with a reported habitual consumption .8 caffeine-containing drinks/d day, high alcohol consumption (.14 units/wk for women; .21 units/wk for men), or intense sporting activities (.10 h/wk) were excluded. Study participants were informed about the aim of the study, and written informed consent was obtained from each participant before the start of the study. The study was approved and conducted in accordance with the guidelines of the ethics committee Comité de Protection des Personnes Sud-Est IV, Lyon, France.
Study design
The study had a double-blind, randomized, placebo-controlled, full factorial parallel design with a 2-wk run-in period followed by an intervention period of 4 wk. It was a bicentric study that was carried out at 2 sites in Grenoble and Lyon, France, between December 2010 and February 2011. Participants who passed the screening and completed the run-in period were sequentially allocated by the clinical investigator into 4 treatment groups according to a preestablished blockwise randomization scheme. Separate computer-generated randomization schedules for men and women were created by a Unilever statistician to stratify subjects by sex with an attempt to achieve a distribution between men and women of 50:50 in each treatment group.
Study products
During the intervention period, participants were instructed to consume one of the following test drinks daily for 4 wk: a 200-mL drink that contained 1) 6 g cocoa powder that naturally provided 150 mg theobromine and 325 mg flavonoids ([cocoa intervention (CC)], 2) 850 mg pure theobromine [theobromine intervention (TB)], 3) 6 g cocoa powder and 850 mg added pure theobromine, which provided a total of 1000 mg theobromine and 325 mg flavonoids [theobromine and cocoa intervention (TB +CC)], or 4) no cocoa powder and no added theobromine (placebo). Test drinks were chocolate-flavored pasteurized acidified milk drinks that were manufactured by Unilever Research & Development. The various test drinks differed to some extent in taste and color. To maintain the blinding of participants and investigators, drinks were supplied in identical tinted bottles that were packed individually for each participant in a neutral box and labeled with the subject code; also participants were instructed not to pour the drink into a glass but to consume it directly out of the tinted bottle. All test drinks provided w80 kcal, 3 g fat, 11 g carbohydrates, and 3 g protein per 200-mL drink. Theobromine was supplied by Fagron; the cocoa powder (Acticoa) was provided by Barry Callebaut. The theobromine, total polyphenol, and cocoa flavonoid (ie, flavanol) concentration of the cocoa powder and test drinks were determined before the start and at the end of the study. Total polyphenols were analyzed by using the Folin-Ciocalteau method (27) , which was adapted to microplate format. Theobromine and flavanol contents were quantified with the HPLC method according to International Standardization Organization standard 14502-2:2005 (E). The response factor for theobromine was determined for correct quantification.
Study procedures
Subjects were instructed to consume the test drink 1 h before the consumed breakfast. Subjects were asked to shake the drink $20 times before use to ensure that the cocoa powder was well dissolved before ingestion.
Throughout both the run-in and intervention periods, subjects were requested to exclude all cocoa-containing products (such as, eg, chocolates, chocolate bars, chocolate drinks, chocolate cookies, chocolate spread, chocolate ice cream, chocolate pudding, chocolate cake, and breakfast cereals with chocolate) from their diets. The consumption of caffeine-containing drinks such as coffee, tea, or cola was restricted to a maximum of 4 cups or cans/d because in the body, caffeine is metabolized into theobromine. The use of supplements that contained theobromine, caffeine, or cocoa and consumption of caffeine-containing energy drinks was prohibited. Beyond these limitations, subjects were asked to maintain their habitual diet and lifestyle routines.
Subjects were instructed to report daily in an intake diary the amount of test product taken, timings of test product and breakfast intakes, and compliance to restrictions concerning the background diet. The importance of the compliance to these instructions was also emphasized during weekly phone calls to study participants. At the end of the intervention period, subjects were asked to return all (used and nonused) bottles of the test product to the study center.
Subjects visited the study center on 2 consecutive days at baseline (ie, on the last day of the run-in period and the first day of the intervention period) and again on 2 consecutive days at the end of the intervention period (ie, on the last day on which the test product was consumed and the day after). On all 4 measurement days, subjects came to the study center in a fasted state not having eaten anything since 2000 and not having drunk anything (except water) after 2200 the previous evening. Breakfast was provided to subjects at the study center 1 h after intake of the test product.
Clinical and laboratory measurements
For the measurement of blood lipids, blood samples were taken on each of the 4 measurement days to take into account the dayto-day variation in blood lipids. Samples taken on the first day of the intervention and the day after the end of the intervention period were used to determine plasma theobromine and caffeine concentrations as additional compliance measures. Measurement days were not scheduled on Mondays to avoid effects of possible deviating behaviors during weekends on blood measurements.
With the use of a venipuncture, fasted blood samples for the measurement of blood lipids were collected into SST II advance BD tubes (Becton Dickinson), and aliquots were transferred into prelabeled polypropylene tubes and frozen at 2208C. At the end of the study, sample tubes were sent to the Laboratoire Biocentre for analysis of blood lipids and lipoproteins. Serum HDL cholesterol, LDL cholesterol, total cholesterol, triacylglycerides, apolipoprotein A-I, and apolipoprotein B were measured with a Hitachi 912 autoanalyzer with the aid of test kits, all provided by Roche Diagnostics GmbH.
For the analysis of theobromine and caffeine plasma concentrations, fasted blood samples were collected into EDTA-3K-coated evacuated tubes and centrifuged at 1500 3 g for 10 min at 48C. The top layer of human plasma was transferred into 3 prelabeled polypropylene tubes and frozen at 2808C. Theobromine and caffeine concentrations were analyzed at Unilever Research & Development. To 400 mL plasma samples, 50 mL internal standard (theobromine-d 6 ) and 750 mL acetonitrile were added. After mixing and centrifugation, the supernatant fluid was analyzed by using liquid chromatography-tandem mass spectrometry (28) . All serum and plasma samples of one subject were analyzed in the same batch.
Body weight was measured at baseline (ie, on the first day of the intervention) and the day after the end of the intervention period early in the morning after an overnight fast. Subjects were weighed in their underwear and with an empty bladder.
In a subsample of the study population (n = 10 per treatment group), 24-h ambulatory blood pressure and heart rate were measured on the last day of the run-in period and the last day of the intervention. Measurements were performed by using an automatic ambulatory blood pressure monitor (ABPM) (Spacelabs 90207; Spacelabs Inc), which was placed on the nondominant arm of subjects. The ABPM device measured systolic blood pressure, diastolic blood pressure, and heart rate every 15 min during the day (0700-2300) and every 30 min during the night (2300-0700). The first ABPM measurement set off in the morning after blood sampling and measurements continued for 24 h. The 40 subjects who underwent the 24-h blood pressure and heart rate measurements were instructed not to consume alcohol-containing beverages, tea, coffee, or grape juice or conduct strenuous physical activities during measurement days to reduce external influences that may have affected blood pressure and heart rate.
Adverse events were monitored throughout the study period, ie, they were spontaneously reported by the subjects or noted by the investigator during one of the visits to the study center.
Statistical analysis
A power calculation indicated that a minimum of 138 subjects were necessary to detect an interaction effect on HDL-cholesterol concentrations of 0.07 mmol/L with an SD of 0.15 in a 2-by-2 full factorial design, testing 2 sided (ie, for a positive or negative effect) with a = 0.05 and b = 0.8. To allow for a dropout rate of 10%, the desired sample size was 152.
Mean values for blood lipid concentrations at baseline and at the end of the intervention were calculated as the average of the measurements taken on the 2 consecutive measurement days. Values for non-HDL cholesterol were calculated by subtracting HDL cholesterol from total cholesterol. HDL-cholesterol:non-HDL-cholesterol and HDL-cholesterol:LDL-cholesterol ratios were determined. Mean 24-h values of diastolic and systolic blood pressure and heart rate were calculated by first taking hourly means of blood pressure or heart rate measurements and discarding any missing values. Hourly means were averaged over 24 h. If $30% of hourly means were missing, no mean 24-h value was calculated, and values were reported as missing completely. Before the analysis, all data were checked for being normally distributed. Triacylglycerol concentrations and HDL-cholesterol:non-HDL-cholesterol and HDL-cholesterol: LDL-cholesterol ratios, and plasma theobromine and caffeine concentrations required log transformation.
Blood lipid and apolipoprotein concentrations and mean 24-h systolic and diastolic blood pressure and heart rate were analyzed for factor effects by using a full factorial analysis with baseline and sex as covariates and factors split up in cocoa (yes or no) and theobromine (yes or no). Also, sex-by-treatment interactions were included in the base model. In addition, age, body weight, and BMI at baseline and changes in body weight and BMI were tested as potential covariates. Variables were only to be included in the model if they were shown to significantly add to the explained variance as measured by using the chi-square-test in the ANOVA table (P # 0.1). Changes in compliance markers (ie, theobromine and caffeine plasma concentrations and body weight) from baseline to the end of the intervention within and between groups were analyzed by using paired sample t tests and ANOVA with Tukey's multiple-difference testing, respectively. P , 0.05 was considered statistically significant.
In addition to a full-analysis-set (FAS) analysis that included all subjects for which end-of-intervention values were available, a per-protocol (PP) analysis was performed, which excluded data from subjects who had been noncompliant with test-product consumption (defined as ,80% of the total intake of test products), had a body weight change .2 kg, or were noncompliant with dietary restrictions (ie, consumed cocoa-containing products in unreasonably high amounts or toward the end of the intervention). These exclusion criteria were applied because noncompliance with test-product intake and the background diet may have blunted the effects of the TB, and weight changes can influence HDL-cholesterol concentrations (29) . All statistical analyses were performed with JMP software (version 9, SAS Institute Inc).
RESULTS
Subject characteristics and compliance measures
Of the 152 subjects randomly assigned over the 4 treatments, 143 subjects completed the intervention period and were available for FAS analysis. This analysis excluded 9 subjects who had discontinued the intervention because of the occurrence of adverse events (n = 8) or personal reasons (n = 1). A flow diagram of participants throughout the study is depicted in Figure 1 . During a blind review, 9 additional subjects were excluded from the PP analyses because they had gained or lost .2 kg in body weight during the study period. Because the PP and FAS analyses showed similar results, only the results of the FAS population (n = 143) are reported.
Baseline characteristics of study participants and key compliance measures per treatment group are shown in Table 1 . Men and women were evenly distributed across and within treatment groups; baseline characteristics were similar between subjects of different groups. The compliance to test-product intake as calculated from the counting of returned empty bottles and recordings in intake diaries was 99.7%. From baseline to the end of the intervention, plasma concentrations of theobromine increased 5-, 17-and 19-fold in the CC, TB, and TB+CC groups, respectively. Plasma caffeine concentrations at baseline and at the end of the intervention were generally low in all groups (ie, ,4 mmol/L), although during the intervention period, caffeine concentrations doubled in the TB+CC group (Table 1) .
Within but not between groups, there were small, significant changes in the mean body weight from baseline to the end of the intervention, which was, however, not considered to be of biological relevance (Table 1) . The body weight, BMI, or age of FIGURE 1. Subject flowchart. Data from all subjects for whom baseline and follow-up measurements were available (ie, FAS) were included in the analysis. *Numbers in italic represent the study population for blood pressure and heart rate measurements. FAS, full analysis set; PP, per protocol. 1 Total number of subjects was n = 152 at baseline and n = 143 at the end of the intervention. There were no significant differences between groups at baseline (P . 0.05; ANOVA).
2 Mean 6 SD; ranges in parentheses (all such values). 3, 4 Significantly different from baseline (paired samples t test): 3 P , 0.0001, 4 P , 0.05. 5 Significantly different from cocoa and placebo groups, P , 0.0001 (ANOVA followed by Tukey's multiple-difference testing). 6 Significantly different from the placebo group, P , 0.05 (ANOVA followed by Tukey's multiple-difference testing). subjects were NS predictors of any outcome measures; therefore, only sex and the baseline value of outcome measures were included as covariates in the ANCOVA model.
Serum lipids and lipoproteins
Descriptive data on serum lipids and lipoproteins at baseline and at the end of the intervention for the 4 groups are shown in Table 2 . After 4 wk of intervention, a significant main effect on HDL-cholesterol concentrations was shown for the TB factor (P , 0.0001) but not for the CC factor ( Table 3 ). The TB increased HDL cholesterol by 0.16 mmol/L. There was no significant interaction effect between TB and CC factors on HDL cholesterol (P = 0.3735). The effect of the TB factor on HDL cholesterol was similar for men and women.
Significant main effects of the TB but not CC factor were also shown for LDL cholesterol and the calculated HDL-cholesterol: non-HDL-cholesterol and HDL-cholesterol:LDL-cholesterol ratios. There were no significant interaction effects of TB and CC factors on any of these variables (Table 3 ). In addition, the TB factor had a significant main effect on increasing apolipoprotein A-I concentrations and decreasing apolipoprotein B concentrations. Also, the CC factor had a small significant effect on apolipoprotein A-I (Table 3 ). There were no significant interaction effects between TB and CC factors on apolipoprotein A-I and apolipoprotein B. No significant factor effects were shown for total cholesterol and triacylglycerol concentrations (Table 3) .
Twenty-four hour blood pressure, heart rate, and adverse effects
Descriptive data of 24-h blood pressure and heart rate at baseline and the end of the intervention for the 4 groups are shown in Table 4 . No significant factor effects were observed for either 24-h systolic or diastolic blood pressure or 24-h heart rate (Table 3) . However, plotting of the hourly mean data showed that heart rate acutely increased by 10-15 beats/min during the first few hours after consumption of the test product in TB and TB+CC groups (data not shown).
Reported adverse effects were mainly seen in TB and TB+CC groups, with 43 and 57 recordings, respectively, compared with 18 and 10 recordings in the CC and placebo groups, respectively. The most commonly reported adverse events were nausea, vomiting, headache, and diarrhea. All except for one of these adverse events were of mild to moderate intensity and resolved before the end of the study. In total, adverse events lead to the premature withdrawal of 8 subjects, of which 6 subjects were in the TB+CC group.
DISCUSSION
This randomized, double-blind, placebo-controlled humanintervention study showed that daily doses of 850 mg theobromine independently increased serum HDL-cholesterol concentrations by 0.16 mmol/L. Cocoa, which delivered 150 mg natural theobromine per daily serving, led to only a modest nonsignificant increase in HDL cholesterol; there was no significant interaction effect between TB and CC factors on raising HDL cholesterol. These findings suggested that theobromine is the major active component in cocoa that is responsible for an increasing HDL-cholesterol effect. The main effect of the TB factor on increasing HDL cholesterol was supported by a significant main effect of the TB factor on an increasing concentration of apolipoprotein A-I, which is the major apolipoprotein of HDL particles.
The findings of this study might explain conflicting results reported by previous intervention studies with cocoa on the effect on HDL-cholesterol concentrations as described in 3 metaanalyses (5-7). Whereas 2 meta-analyses reported either a nonsignificant small reduction (7) or nonsignificant small increase in HDL-cholesterol concentrations (5) after the intake of cocoa products, a third meta-analysis reported a significant beneficial effect of cocoa products on raising HDL cholesterol but with significant heterogeneity in individual studies (6) . A common feature of studies that showed an HDL-cholesterol-increasing effect of cocoa was the use of theobromine-free control products (8) (9) (10) (11) (12) , whereas studies that controlled for theobromine intake in control and intervention products did not find an effect (14, (16) (17) (18) 20) . However, there were a few studies that failed to show an HDL-cholesterol increasing effect of cocoa despite the use of a theobromine-free control product (19, (30) (31) (32) (33) . However, this lack of an effect may be explained by a too short intervention period (ie, 2 wk) in these studies (30) (31) (32) (33) or a too low theobromine content of the test product (ie, 26 mg per daily dose) (19) . Also, in the current study, the CC treatment, which naturally contained 150 mg theobromine, caused an only small, nonsignificant increase in HDL cholesterol, which indicated that a higher dose of theobromine may be necessary to show a substantial effect on serum HDL cholesterol. The prevalence of low serum HDL-cholesterol concentrations is w26-80% in adult populations across the globe (34) . However, the current study showed that theobromine could increase HDL cholesterol even in healthy people with adequate basal (35, 36) , modest alcohol consumption (37) , or loss of w5-10% of body weight (29)]. In addition to an increase in HDL cholesterol, supplementation with theobromine also resulted in a moderate reduction of LDLcholesterol concentrations, which further improved the blood lipid profile. In this study, no significant factor effects on 24-h blood pressure and heart rate were shown, although an acute postintake increase in heart rate was observed in TB and TB+CC groups. This cardiac stimulating effect, which is an undesirable side effect, was also reported in previous studies with theobromine or other methylxanthines (24, 25) .
A strength of our study was the high quality of execution and data generation; ,6% of participants withdrew from the study prematurely. In addition, the reported compliance to test-product intake was very high and was further supported by observed increases in theobromine plasma concentrations in active treatment groups. The doubling of plasma caffeine concentrations in the TB+CC group may be explained by the competition between caffeine and theobromine, which are both methylxanthines, for metabolic pathways.
Because HDL cholesterol can be influenced by diet and lifestyle behaviors, such as physical exercise and alcohol consumption, we excluded subjects with extreme physical activity or high alcohol intake from participation; through daily selfrecordings of compliance, we discouraged changes in and captured deviations from the habitual diets and lifestyles of participants throughout the study period. However, the lack of information on actual physical activity and a complete dietary assessment can be seen as a limitation of our study because the diets and lifestyles of subjects in the 4 treatment groups may have differed at baseline or changed differentially throughout the study period.
Another limitation of this study is that we did not investigate possible physiologic mechanisms of action that could explain how theobromine increases HDL cholesterol. HDL-cholesterol metabolism is rather complex, and several biological targets are known to affect serum HDL-cholesterol concentrations, such as the enhancement of apolipoprotein A-I production; enhancement of ATP-binding cassette transporter A1/G1 activity, or inhibition of cholesteryl ester transfer protein (CETP) activity. Post-hoc, we did analyze CETP activity in remaining plasma samples of subjects in the placebo and TB group, showing no effect of theobromine on CETP activity (data not shown). Clearly, additional studies are required to address the effects of theobromine on possible biological targets to explore the underlying mechanisms of action for the increase in HDL cholesterol. In addition, there is no current indication of whether the increase in HDL-cholesterol concentrations with theobromine affects HDL functionality.
A number of epidemiologic studies, including prospective observation studies, have shown that a 1% increase in HDL cholesterol is linked to a 1-3% reduction in CVD risk, even when controlled for other risk variables (38) (39) (40) . Although elevated LDL cholesterol is the most important lipid target in the prevention and treatment of CVD, and despite powerful treatment options to lower LDL-cholesterol concentrations, there remains substantial residual cardiovascular risk, which can be further reduced by targeting other blood lipids such as raising HDL cholesterol (41) . In addition, epidemiologic data have shown that increasing HDL-cholesterol concentrations can further reduce CVD risk even in people with adequate LDL-cholesterol concentrations (42, 43) . However, there is currently no direct clinical evidence that increasing HDL-cholesterol concentrations per se has a protective effect on reducing CVD risk.
Still, the observed beneficial effects of theobromine on blood lipids suggested that theobromine may be a promising dietary ingredient in the prevention of CVD. Chocolate is by far the main source of theobromine in the Western diet (25) . However, to deliver 850 mg theobromine (ie, the daily dose which was provided by the TB treatment in the current study), w100 g dark chocolate or w200 g milk chocolate are needed (25) . Nevertheless, this amount of chocolate also provides w20-40 g saturated fat and w540-1,080 kcal, respectively (44) . Therefore, other ways to increase dietary theobromine intake are required.
In conclusion, to our knowledge, this is the first study to show that a daily intake of 850 mg theobromine independently and significantly increases HDL-cholesterol concentrations by 0.16 mmol/L in healthy subjects. Together with the lack of a significant main effect of cocoa and interaction effect, this result suggests that theobromine is the major active compound in cocoa that is responsible for the beneficial HDL-cholesterol-increasing effect. We thank all participants who took part in this study. We also thank the clinical investigators Yves Donazzolo, Mathilde Latreille, and Stéphanie Delcroix and the project manager Isabelle Blank at Eurofins Optimed for the execution of the study throughout and for taking care of study participants. In addition, we thank our following colleagues at Unilever Research & Development: Richard Draijer, Yuguang Lin, Mario Vermeer, and Winfried Theis for their scientific input and critical review of the manuscript; Jamy von Harras and Koos Scholtes for the development and production of test products; Jeroen Sterken for coordinating the logistics of test products; and Christian Grün, Monique van der Burg, and Ruud Poort for performing the chemical analyses.
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